Coronavirus: 'breakthrough' protein treatment could boost recovery rates, study suggests

Trials carried out in the UK have produced promising results

Medical trials undertaken in the UK have produced promising results in the ongoing fight against Covid-19. AFP

A new treatment for Covid-19 has produced encouraging early results in trials on patients in the UK.

While still preliminary, the findings suggest that patients are more than twice as likely to recover from infection after inhaling a form of interferon beta (IFN-beta), a protein used by the body’s virus-fighting system.

Patients also had a lower risk of developing severe disease, needing ventilation, suffered less breathlessness and also spent significantly less time in hospital.

The results – which have yet to be published in a peer-reviewed journal – “could signal a major breakthrough”, according to Synairgen, the drug research company in Southampton, UK, which developed the treatment.

A municipal worker wears a face mask and shield at the Bosa neighborhood, one of the areas with more Covid19 cases in Bogota, Colombia. AFP

Medical workers carry a man who is the last patient recovered from the Covid19 coronavirus infection in the Wuhan, pulmonary hospital before he leaves the hospital in Wuhan, in China's central Hubei province. AFP

A nurse changes the medications of a patient suffering from the coronavirus disease at the Intensive Care Unit of Emilio Ribas Institute in Sao Paulo, Brazil. Reuters

A woman is disinfected at her request at the entrance of Cariacu, Ecuador. Every vehicle or person entering the community has to be disinfected in an attempt to curb the spread of the coronavirus. AP Photo

An employee of the Mugda Medical College and Hospital collects a swab sample from a resident to test for the Covid19 coronavirus, in Dhaka, Bangladesh. AFP

An official sprays disinfectant inside a school amid the ongoing coronavirus pandemic in Denpasar, Bali, Indonesia. EPA

A man takes a customer's body temperature wearing a face mask before entering a shopping area, after the Colombian government decided to relax social restrictions amid the outbreak of the coronavirus disease, in Bogota, Colombia. Reuters

Police officers wearing facemasks stand guard next to a street sealed by the authorities at I-8 residential sector in Islamabad as cases of COVID-19 coronavirus continue to rise in Pakistan. AFP

An employee wearing a protective mask holds Mickey and Minnie Mouse shaped balloons at Walt Disney Co.'s Disneyland Resort in Hong Kong, China. Bloomberg

A man wearing a mask to help curb the spread of the new coronavirus is reflected in the mirror of his motorcycle in Cariacu, Ecuador. AP Photo

A sign that reads, "Mandatory to wear a mask on all the site", is seen at the entrance of the Eiffel Tower as she gets ready to re-open to the public following the coronavirus outbreak, in Paris, France. Reuters

A man wearing a face mask rides the subway, following new cases of the coronavirus disease infections in Beijing, China. Reuters

Doug Hassebroek pours confetti over his daughter Lydia, celebrating her graduation ceremony at their home during the outbreak of coronavirus disease in Brooklyn, New York, USA. Reuters

Carol Reihart, a certified nursing assistant at Little Sisters of the Poor, and resident Kay Canyock wave to cars filled with family, friends, and volunteers during a parade to celebrate Canyock's 100th birthday and the birthday of fellow resident Mary Sahayda, who turned 103 on the same day, at Little Sisters of the Poor home for the elderly in Pittsburgh, Pennsylvania, USA. Pittsburgh Post-Gazette via AP

Leonardo Da Vinci bookstore owner, Brazilian bookseller Daniel Louzada,packs a book for an online order placed on the bookstore's website, inaugurated during the pandemic since the store was closed to follow social distance measures to curb the spread of the new coronavirus in Rio de Janeiro, Brazil. AFP

Michael Antonorsi, Chief Joy Activator at Chuao Chocolatier, sits in a hammock while working on a laptop from his beachfront home during the outbreak of the coronavirus in Leucadia, California, USA. Reuters

A policeman stands guard along the empty famous white beach of Boracay Island in central Philippines, as community quarantine against Covid19 still continues throughout the country, with foreign tourists still banned on beaches. AFP

A priest walks along a dusty path at the Martires 19 de Julio cemetery, on the outskirts of Lima, Peru as the death toll remains unabated in Peru's capital. AP Photo

"We couldn't have expected much better results than these,” Richard Marsden, the company's chief executive, told the BBC.

He said his company was about to present its work to medical regulators in the first step towards having the treatment approved for use.

One major caveat about the findings is that they come from a relatively small study of 101 patients.

As a result, the evidence of benefit still carries considerable uncertainty. Some of the findings are also only barely statistically significant, the minimum standard needed to be taken seriously by regulators.

Nevertheless, the results to date suggest the treatment could be a “game changer”, according to Professor Tom Wilkinson of the University of Southampton, who organised the clinical trial across nine UK hospitals.

These were so-called double-blind randomised placebo-controlled trials, meaning both patients and doctors were unaware of who received the treatment or an inactive placebo, and that other forms of bias had been minimised. Such trials are regarded as the most reliable way of testing a new treatment.

The results are also consistent with what is known about IFN-beta. Naturally produced by the body’s immune system, this protein orchestrates the response to viral infections.

Since Covid-19 first emerged last December, studies have shown that older people and those with chronic health conditions – two of the most vulnerable groups of Covid-19 patients – also have relatively low IFN-beta levels.

It is also known that coronaviruses – including Sars-CoV-2, responsible for Covid-19 – can suppress the production of the protein.

This has led researchers to suspect that giving patients IFN-beta following infection could improve the chances of survival.

Promising results with patients with Sars and Mers led the World Health Organisation to include IFN-beta in its list of potentially useful treatments for Covid-19 when used with other drugs. However, there has been concern that its effectiveness depends on how it is administered.

Remarkably, the new results suggest IFN-beta is highly effective if simply inhaled via a nebuliser. Previous studies of patients with asthma and other breathing disorders also suggest the treatment is safe and does not interact with many other drugs. It may also be effective in combating the virus soon after infection.

Combined with the urgent need for such treatment, it is likely that Synairgen will win emergency approval for the therapy.

The company is understood to have begun production several months ago in anticipation of the positive results, and aims to deliver hundreds of thousands of doses by the winter.

“Our efforts are now focused on working with the regulators and other key groups to progress this potential Covid-19 treatment as rapidly as possible”, said Mr Marsden.

Robert Matthews is Visiting Professor of Science at Aston University, Birmingham, UK